In future work, UK CF Registry data combined with the target trial framework could be used to repeat our study in a post-modulator population, including in groups with and without access to, or intolerant of, CFTR modulator treatments, and to answer related questions about discontinuing treatment in those using CFTR modulators. This evidence concerns the gene CFTR and cystic fibrosis.